Treatment management of patients with systemic lupus erythematosus: a delphi consensus analysis
Open Access
- 10 October 2022
- journal article
- research article
- Published by Aboutscience Srl in Global and Regional Health Technology Assessment
- Vol. 9, 123-132
- https://doi.org/10.33393/grhta.2022.2470
Abstract
Background: Systemic lupus erythematosus (SLE) is associated with clinical burden for the patient and organ damage. The development of therapies for SLE has been constrained by clinical and biologic heterogeneity. These represent challenges in clinical trial design and endpoint selection. Objective: To identify the most relevant descriptors for efficacy, endpoints, disease activity, organ damage, quality of life (QoL), and Patient Reported Outcome Measures (PROMs) in the treatment of SLE. Methods: A Delphi study was conducted using a national expert panel of clinicians in the treatment of SLE. A steering committee composed of 3 opinion leaders with deep expertise in SLE treatment was defined. The steering committee analyzed and appraised the evidence, designed the Delphi study, defined the statements, and analyzed the expert panel responses. A 2-round Delphi survey was conducted. Participants were asked to rate the statements using a five-point Likert scale. Results: Nine experts participated in the Delphi survey. After the two rounds, the consensus was reached on 18 of the 23 statements: 2 statements were included in the “efficacy” domain, 2 in the “glucocorticoid-sparing” domain, 2 in the “endpoint evaluation” domain, 4 in the “score” domain, 1 in the “disease activity” domain, 1 in the “organ damage” domain, 1 in the “QoL” domain, 2 in the “PROMs” domain, 1 in the “AIFA monitoring” domain and 2 in the “extra” domain. No statements reached consensus within the “onset” domain. Conclusion: In this Delphi study, 18 statements across 11 domains were agreed upon for the treatment of SLE.Keywords
This publication has 36 references indexed in Scilit:
- Early Lupus Project – A multicentre Italian study on systemic lupus erythematosus of recent onsetLupus, 2015
- Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus ErythematosusBioMed Research International, 2014
- Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre studyAnnals Of The Rheumatic Diseases, 2013
- Emerging therapies for systemic lupus erythematosus — Focus on targeting interferon-alphaClinical Immunology, 2012
- Unmet medical needs in systemic lupus erythematosusArthritis Research & Therapy, 2012
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis & Rheumatism, 2011
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialThe Lancet, 2011
- Understanding the Epidemiology and Progression of Systemic Lupus ErythematosusSeminars in Arthritis and Rheumatism, 2010
- Novel evidence‐based systemic lupus erythematosus responder indexArthritis Care & Research, 2009
- Etiology, environmental relationships, epidemiology, and genetics of systemic lupus erythematosusCurrent Opinion in Rheumatology, 1995